

Summary of Product Characteristics

1 NAME OF THE MEDICINAL PRODUCT

Avelox 400 mg film-coated tablets

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

1 film-coated tablet contains 400 mg moxifloxacin (as hydrochloride).

Excipient with known effect: The film-coated tablet contains lactose monohydrate.

For the full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Film-coated tablet

Product imported from Greece

Dull red film-coated tablet with an oblong, convex shape with facet, a dimension of 17 x 7 mm, and marked with "M400" on one side and "BAYER" on the other side.

4 CLINICAL PARTICULARS

As per PA1410/027/001

5 PHARMACOLOGICAL PROPERTIES

As per PA1410/027/001

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Tablet core:

Microcrystalline cellulose
Croscarmellose sodium
Lactose monohydrate
Magnesium stearate

Film-coat:

Hypromellose
Macrogol 4000
Ferric oxide (E172)
Titanium dioxide (E171)

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

The shelf life expiry date for this product shall be the date shown on the blister and outer package of the product on the market in the country of origin.

6.4 Special precautions for storage

Do not store above 25°C.
Store in the original package in order to protect from moisture.

6.5 Nature and contents of container

The film-coated tablets are available in packs of 5 film-coated tablets

6.6 Special precautions for disposal and other handling

No special requirements.

7 PARALLEL PRODUCT AUTHORISATION HOLDER

Lexon (UK) Ltd
Unit 18
Oxleasow Road
East Moons Moat
Redditch
Worcestershire
B98 0RE
United Kingdom

8 PARALLEL PRODUCT AUTHORISATION NUMBER

PPA1097/025/001

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 21st July 2017

10 DATE OF REVISION OF THE TEXT